Congress: Movement Disorder Society (MDS) International Congress 2026 Location: Seoul, Korea — COEX Convention and Exhibition Center Dates: October 4-8, 2026
This page synthesizes research on GBA and LRRK2 genetic risk factors, gene-environment interactions, and their implications for Parkinson's disease pathogenesis and therapeutic targeting presented at MDS 2026.
[GBA](/genes/gba) (Glucocerebrosidase) and [LRRK2](/genes/lrrk2) (Leucine-Rich Repeat Kinase 2) represent the two most significant genetic risk factors for Parkinson's disease (PD). Together, they account for a substantial proportion of both familial and sporadic PD cases. MDS 2026 highlighted recent advances in understanding how these genetic risk factors interact with environmental exposures to modify disease risk, phenotype, and progression.
[GBA](/genes/gba) variants are the most significant genetic risk factor for sporadic PD, with 5-10% of PD patients carrying pathogenic variants[@gba2024]. Unlike monogenic forms, GBA-associated PD demonstrates a complex inheritance pattern with variable penetrance.
Congress: Movement Disorder Society (MDS) International Congress 2026 Location: Seoul, Korea — COEX Convention and Exhibition Center Dates: October 4-8, 2026
This page synthesizes research on GBA and LRRK2 genetic risk factors, gene-environment interactions, and their implications for Parkinson's disease pathogenesis and therapeutic targeting presented at MDS 2026.
[GBA](/genes/gba) (Glucocerebrosidase) and [LRRK2](/genes/lrrk2) (Leucine-Rich Repeat Kinase 2) represent the two most significant genetic risk factors for Parkinson's disease (PD). Together, they account for a substantial proportion of both familial and sporadic PD cases. MDS 2026 highlighted recent advances in understanding how these genetic risk factors interact with environmental exposures to modify disease risk, phenotype, and progression.
[GBA](/genes/gba) variants are the most significant genetic risk factor for sporadic PD, with 5-10% of PD patients carrying pathogenic variants[@gba2024]. Unlike monogenic forms, GBA-associated PD demonstrates a complex inheritance pattern with variable penetrance.
| Mutation Category | Common Variants | Effect on GCase Activity | PD Risk |
|------------------|-----------------|--------------------------|---------|
| Severe | L444P, 84GG, IVS2+1G>A | <5% residual activity | 20-30x increased |
| Moderate | N370S, E326K | 15-40% residual activity | 5-10x increased |
| Risk-modifying | T369M, P387L | Mild reduction | 1.5-3x increased |
The relationship between GBA genotype and clinical phenotype in PD follows a dose-response pattern based on residual GCase activity:
| Genotype | Age of Onset | Motor Severity | Cognitive Decline | Progression Rate |
|----------|--------------|----------------|-------------------|------------------|
| N370S heterozygous | 55-60 years | Moderate | Moderate | Intermediate |
| L444P heterozygous | 50-55 years | Severe | Early/frequent | Fast |
| 84GG heterozygous | 48-52 years | Severe | Very early | Very fast |
| Compound heterozygous | 45-50 years | Very severe | Very early | Very fast |
GBA carrier frequency varies significantly across populations:
| Population | PD Carrier Frequency | General Population | Odds Ratio |
|------------|---------------------|-------------------|------------|
| Ashkenazi Jewish | 15-20% | 5-6% (N370S) | 5-10x |
| European descent | 5-10% | 1-2% | 5-7x |
| East Asian | 3-5% | <1% | 3-5x |
| African descent | 2-4% | <1% | 2-4x |
Key insight: The carrier frequency of severe GBA variants (L444P, 84GG) in PD patients is approximately 10x higher than in the general population, while risk-modifying variants show more modest enrichment.
The connection between GBA dysfunction and PD involves multiple interconnected pathways:
GBA-PD represents a distinct clinical subtype with characteristic features:
| Approach | Mechanism | Clinical Status | Notes |
|----------|-----------|-----------------|-------|
| Ambroxol | Pharmacological chaperone | Phase 2/3 | Restores GCase function |
| Venglustat | Substrate reduction | Phase 2 | Reduces glucosylceramide |
| AAV-GBA | Gene therapy | Phase 1/2 | Restores enzyme expression |
| Eliglustat | GCS inhibitor | Approved for GD | Brain-penetrant |
[LRRK2](/genes/lrrk2) is the most common monogenic cause of PD, accounting for approximately 5-10% of familial PD and 1-3% of sporadic PD[@cookson2023].
| Variant | Domain | Effect | Population Prevalence |
|---------|--------|--------|----------------------|
| G2019S | Kinase | ↑ Kinase activity 2-3x | ~5% familial, ~1% sporadic PD |
| R1441C/G/H | ROC | ↓ GTPase activity | Basque, worldwide |
| N1437D | ROC | ↓ GTPase activity | Norwegian |
| Y1699C | COR | Intermediate | Worldwide |
| I2020T | Kinase | ↑ Kinase activity | Japanese families |
LRRK2 genotype correlates with specific clinical features:
| Mutation | Age of Onset | Motor Phenotype | Cognitive Features |Penetrance by Age 80 |
|---------|--------------|-----------------|-------------------|---------------------|
| G2019S | 55-65 years | Typical PD | May develop later | 70-80% |
| R1441C/G | 50-60 years | More variable | Earlier dementia | 60-70% |
| Y1699C | 55-65 years | Typical | Variable | 50-60% |
| I2020T | 55-65 years | Typical | Variable | 50-70% |
LRRK2 variant frequency shows marked geographic and ethnic variation:
| Population | G2019S Frequency | Other Common Variants |
|------------|-----------------|----------------------|
| North African | 10-15% (familial) | — |
| European | 5% (familial), 1% (sporadic) | R1441C/G (Basque) |
| East Asian | 0.5-1% | G2385R, R1628P |
| South Asian | 2-3% | — |
| Ashkenazi Jewish | 5-10% | — |
Penetrance considerations: LRRK2 penetrance is incomplete and age-dependent. G2019S carriers have approximately 70-80% lifetime risk of developing PD, with risk increasing sharply after age 50.
LRRK2 participates in multiple cellular pathways relevant to PD pathogenesis:
Multiple LRRK2 inhibitors have advanced through clinical development:
| Drug | Company | Mechanism | Stage | Key Challenges |
|------|---------|-----------|-------|-----------------|
| DNL151/DNL312 | Denali/Biogen | ATP-competitive | Phase 2/3 | BBB penetration |
| BIIB122 | Biogen | ATP-competitive | Phase 2b | Peripheral toxicity |
| PF-06649751 | Pfizer | ATP-competitive | Phase 1 | Long-term safety |
Novel therapeutic modalities include:
MDS 2026 featured significant new research on how genetic susceptibility factors interact with environmental exposures to modify PD risk. This represents a critical frontier in understanding disease etiology and developing prevention strategies.
Gene-environment interactions (GxE) in PD follow several patterns:
The strongest gene-environment interaction evidence involves LRRK2 and pesticide exposure:
LRRK2 variants modify risk associated with:
The relationship between smoking and PD is modified by GBA status:
GBA variants modify air pollution-related PD risk:
Challenges in studying gene-environment interactions:
| Genetic Subtype | Environmental Factor | Therapeutic Strategy | Development Stage |
|-----------------|---------------------|---------------------|-------------------|
| LRRK2 G2019S | Pesticide exposure | Kinase inhibitors | Phase 2/3 |
| GBA1 | Air pollution | Enzyme enhancement | Phase 2 |
| LRRK2 + GBA1 | Multiple | Combination therapy | Preclinical |
| Any | Solvents | Neuroprotective agents | Preclinical |
A subset of PD patients carry variants in both LRRK2 and GBA, representing a unique genetic subset with modified risk and therapeutic implications:
| Variant Combination | Clinical Feature | Therapeutic Approach |
|---------------------|-----------------|---------------------|
| LRRK2 + GBA1 | Earliest onset (~50 years), fastest progression | Combination therapy |
| LRRK2 + GBA1 | Highest cumulative risk | Kinase inhibitor + chaperone |
| LRRK2 only | Typical LRRK2-PD phenotype | LRRK2 inhibitors |
| GBA only | Typical GBA-PD phenotype | Enzyme enhancement |
Clinical trial considerations: Combined carriers may benefit from combination approaches targeting both LRRK2 kinase hyperactivity and GCase deficiency. Enrollment in genotype-stratified trials should consider this patient subset.
For individuals with genetic susceptibility:
Based on gene-environment interaction research:
MDS 2026 highlighted several emerging areas: